Navigation Links
Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation

Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target Tuesday, March 27, 2007 Presentation: Isis Pharmaceuticals' Live Analyst/Investor Webcast Time: 7:00 a.m. CT Where: www.isispharm.com How: Live over the Internet -- select the link on Isis' home page at the address above.

If you are unable to participate during the live webcast, the presentation will be available for replay at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of ov
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... 2014  Novation, the leading health care supply ... new IT value-added reseller (VAR) national contracts that ... IT goods and services at lower costs. These ... as value-added services such as initiative assistance and ... Novation agreements were awarded to CDW Government, Paragon ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ... dermatology for clinical and aesthetic dermatology practitioners in the ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very ... Mark King as its new Chief Executive Officer.  ... Operating Officer, in which he has overseen the company,s ... Mississippi , and Costa Rica.  Mr. King ... broad-based operations, sales, engineering and manufacturing experience in medical ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Low birth weight, less breastfeeding create later health risks 2
... YORK, March 7 The following statement is,from Hughes ... Cotlar, LLP:, United States District Judge Eldon E. ... and Deputy Special Masters who will decide,any appeals taken ... resolution program for Vioxx product liability litigation in the,United ...
... has named 13 translational researchers as the 2008 ... Research. The awards, which provide $150,000 per ... support established, independent physician-scientists who are dedicated to ... patient treatmentand mentoring physician-scientist trainees. , The ...
... March 7 Duane Reade Holdings, Inc. today,announced that ... fourth,quarter and full year 2007 financial results before the ... release, the Company will hold a conference,call on Thursday, ... Interim Chief Executive Officer and Chief Marketing Officer, and,John ...
... Tenn., March 7 HCA Inc. announced today the,final results ... million of,its debt securities specified in the table below. The ... 6, 2008. The tender offer was,made on the terms and ... dated February 7, 2008 and the related Letter of Transmittal., ...
... UC Irvine researchers have discovered a dramatically improved method ... easier for scientists to study and potentially treat thousands ... and diabetes. , The technique for the first time ... rates and increase the efficiency of inserting DNA into ...
... TEMECULA, Calif., March 7 Raintree Systems, ... practice management,and electronic medical records solutions, releases ... medical record product for,Bariatric Surgery., The ... for a,single center and enterprise-level implementations; thus ...
Cached Medicine News:Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 2Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 4Health News:Burroughs Wellcome Fund grants $9.75 million towards translational researchers 2Health News:HCA Announces Final Results for its Debt Tender Offer 2Health News:HCA Announces Final Results for its Debt Tender Offer 3Health News:HCA Announces Final Results for its Debt Tender Offer 4Health News:New stem cell technique improves genetic alteration 2Health News:New stem cell technique improves genetic alteration 3Health News:Raintree Systems Launches the First Integrated Practice Management and Electronic Medical Records Application Within the Bariatric Surgery Industry 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: